Award Number: W81XWH-10-1-0755 TITLE: Fibronectin Matrix Remodeling in the Regulation of the Inflammatory Response within the Lung: An Early Step in Lung Cancer Progression PRINCIPAL INVESTIGATOR:
暂无分享,去创建一个
A. Prasad | P. McKeown-Longo | D. Ph. | S. B. | C. Horzempa | A. Ambesi | S. B | Aparna Prasad
[1] David M. Jones,et al. The First Type III Domain of Fibronectin is Associated with the Expression of Cytokines within the Lung Tumor Microenvironment , 2011, Journal of Cancer.
[2] P. McKeown-Longo,et al. The First Type III Repeat in Fibronectin Activates an Inflammatory Pathway in Dermal Fibroblasts* , 2010, The Journal of Biological Chemistry.
[3] A. MacKinnon,et al. The molecular and cellular biology of lung cancer: identifying novel therapeutic strategies. , 2010, British medical bulletin.
[4] A. Kho,et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression , 2010, The Journal of cell biology.
[5] E. Abraham,et al. Toll-like receptors 2 and 4: initiators of non-septic inflammation in critical care medicine? , 2010, Intensive Care Medicine.
[6] K. Midwood,et al. DAMPening Inflammation by Modulating TLR Signalling , 2010, Mediators of inflammation.
[7] R. Dhir,et al. Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion. , 2010, Cancer research.
[8] K. Moore,et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer , 2009, Nature Immunology.
[9] Lei Liu,et al. Development of a highly metastatic model that reveals a crucial role of fibronectin in lung cancer cell migration and invasion , 2010, BMC Cancer.
[10] S. Rankin,et al. CXCR2 Mediates the Recruitment of Endothelial Progenitor Cells During Allergic Airways Remodeling , 2009, Stem cells.
[11] Mikala Egeblad,et al. Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling , 2009, Cell.
[12] Gina Lee,et al. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer , 2009, Current opinion in pulmonary medicine.
[13] P. McKeown-Longo,et al. Anastellin, the Angiostatic Fibronectin Peptide, Is a Selective Inhibitor of Lysophospholipid Signaling , 2009, Molecular Cancer Research.
[14] A. M. Houghton,et al. Common origins of lung cancer and COPD , 2008, Nature Medicine.
[15] Kristopher E Kubow,et al. Fibronectin in aging extracellular matrix fibrils is progressively unfolded by cells and elicits an enhanced rigidity response. , 2008, Faraday discussions.
[16] J. Bai,et al. Inhibitory role of focal adhesion kinase on anoikis in the lung cancer cell A549 , 2008, Cell biology international.
[17] Ann Richmond,et al. Role of chemokines in tumor growth. , 2007, Cancer letters.
[18] Ying Zheng,et al. Nicotine stimulates human lung cancer cell growth by inducing fibronectin expression. , 2007, American journal of respiratory cell and molecular biology.
[19] D. Hocking,et al. Identification of the Heparin-binding Determinants within Fibronectin Repeat III1 , 2006, Journal of Biological Chemistry.
[20] J. Burger,et al. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells , 2005, Oncogene.
[21] P. McKeown-Longo,et al. Anastellin, a fragment of the first type III repeat of fibronectin, inhibits extracellular signal-regulated kinase and causes G(1) arrest in human microvessel endothelial cells. , 2005, Cancer research.
[22] P. McKeown-Longo,et al. Stimulation of extracellular matrix remodeling by the first type III repeat in fibronectin , 2003, Journal of Cell Science.
[23] M. Yi,et al. A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. , 2001, Proceedings of the National Academy of Sciences of the United States of America.